In addition, autocrine/paracrine prolactin appears to be a survival factor in this subpopulation of breast cancer cells and is induced by treatment with doxorubicin or paclitaxel, as treatment with the PRLR antagonist Δ1–9 potentiates the efficacy of such drugs. The gene discussed is PRLR; the disease is breast carcinoma.